|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CNNM4 |
Gene summary for CNNM4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CNNM4 | Gene ID | 26504 |
| Gene name | cyclin and CBS domain divalent metal cation transport mediator 4 | |
| Gene Alias | ACDP4 | |
| Cytomap | 2q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q6P4Q7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 26504 | CNNM4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.90e-03 | -1.44e-01 | 0.0155 |
| 26504 | CNNM4 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.86e-11 | 6.35e-01 | -0.1808 |
| 26504 | CNNM4 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.44e-28 | 8.99e-01 | -0.1954 |
| 26504 | CNNM4 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.53e-05 | 1.09e+00 | -0.2602 |
| 26504 | CNNM4 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.65e-03 | 4.71e-01 | -0.1207 |
| 26504 | CNNM4 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.82e-04 | 6.65e-01 | -0.1526 |
| 26504 | CNNM4 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.32e-11 | 7.34e-01 | -0.1464 |
| 26504 | CNNM4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.90e-03 | 4.09e-01 | -0.059 |
| 26504 | CNNM4 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.56e-05 | 7.57e-01 | -0.2061 |
| 26504 | CNNM4 | F007 | Human | Colorectum | FAP | 6.32e-04 | -3.93e-01 | 0.1176 |
| 26504 | CNNM4 | A002-C-010 | Human | Colorectum | FAP | 2.02e-04 | -2.92e-01 | 0.242 |
| 26504 | CNNM4 | A001-C-207 | Human | Colorectum | FAP | 4.53e-02 | -2.83e-01 | 0.1278 |
| 26504 | CNNM4 | A015-C-203 | Human | Colorectum | FAP | 2.86e-14 | -3.09e-01 | -0.1294 |
| 26504 | CNNM4 | A015-C-204 | Human | Colorectum | FAP | 6.95e-05 | -2.73e-01 | -0.0228 |
| 26504 | CNNM4 | A002-C-201 | Human | Colorectum | FAP | 3.07e-11 | -3.67e-01 | 0.0324 |
| 26504 | CNNM4 | A002-C-203 | Human | Colorectum | FAP | 1.56e-03 | -2.59e-01 | 0.2786 |
| 26504 | CNNM4 | A001-C-119 | Human | Colorectum | FAP | 4.79e-03 | -1.88e-01 | -0.1557 |
| 26504 | CNNM4 | A001-C-108 | Human | Colorectum | FAP | 1.38e-07 | -2.40e-01 | -0.0272 |
| 26504 | CNNM4 | A002-C-205 | Human | Colorectum | FAP | 3.58e-09 | -2.52e-01 | -0.1236 |
| 26504 | CNNM4 | A001-C-104 | Human | Colorectum | FAP | 3.30e-03 | -2.78e-01 | 0.0184 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0035725 | Colorectum | FAP | sodium ion transmembrane transport | 44/2622 | 178/18723 | 9.31e-05 | 1.60e-03 | 44 |
| GO:0006814 | Colorectum | FAP | sodium ion transport | 54/2622 | 245/18723 | 3.98e-04 | 4.85e-03 | 54 |
| GO:1903830 | Colorectum | FAP | magnesium ion transmembrane transport | 7/2622 | 17/18723 | 5.62e-03 | 3.61e-02 | 7 |
| GO:0015693 | Colorectum | FAP | magnesium ion transport | 7/2622 | 18/18723 | 8.10e-03 | 4.77e-02 | 7 |
| GO:00357251 | Colorectum | CRC | sodium ion transmembrane transport | 39/2078 | 178/18723 | 2.30e-05 | 6.60e-04 | 39 |
| GO:00068141 | Colorectum | CRC | sodium ion transport | 49/2078 | 245/18723 | 3.01e-05 | 7.86e-04 | 49 |
| GO:19038301 | Colorectum | CRC | magnesium ion transmembrane transport | 7/2078 | 17/18723 | 1.46e-03 | 1.57e-02 | 7 |
| GO:00156931 | Colorectum | CRC | magnesium ion transport | 7/2078 | 18/18723 | 2.16e-03 | 2.11e-02 | 7 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CNNM4 | SNV | Missense_Mutation | rs760527932 | c.1735N>A | p.Leu579Ile | p.L579I | Q6P4Q7 | protein_coding | tolerated(0.07) | probably_damaging(0.976) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| CNNM4 | SNV | Missense_Mutation | c.1276G>C | p.Asp426His | p.D426H | Q6P4Q7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CNNM4 | SNV | Missense_Mutation | c.469N>A | p.Asp157Asn | p.D157N | Q6P4Q7 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-AO-A12D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| CNNM4 | SNV | Missense_Mutation | c.1182N>A | p.Phe394Leu | p.F394L | Q6P4Q7 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD | |
| CNNM4 | SNV | Missense_Mutation | c.1030N>T | p.Met344Leu | p.M344L | Q6P4Q7 | protein_coding | tolerated(0.39) | possibly_damaging(0.456) | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
| CNNM4 | insertion | Nonsense_Mutation | novel | c.932_933insCATTACACCAAAATGAA | p.Leu312IlefsTer5 | p.L312Ifs*5 | Q6P4Q7 | protein_coding | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CNNM4 | deletion | Frame_Shift_Del | novel | c.1826delN | p.Asp610ThrfsTer20 | p.D610Tfs*20 | Q6P4Q7 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| CNNM4 | SNV | Missense_Mutation | novel | c.924C>A | p.Phe308Leu | p.F308L | Q6P4Q7 | protein_coding | tolerated(0.82) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CNNM4 | SNV | Missense_Mutation | rs201310811 | c.1792G>A | p.Ala598Thr | p.A598T | Q6P4Q7 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CNNM4 | SNV | Missense_Mutation | novel | c.616N>T | p.Leu206Phe | p.L206F | Q6P4Q7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C5-A901-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |